|drug1643||Inactivated SARS-CoV-2 vaccine (Vero cell) Wiki||1.00|
There is one clinical trial.
This is a randomized, double blind, placebo parallel-controlled phase III clinical trial to evaluate the efficacy, immunogenicity and safety of the inactivated SARS-CoV-2 Vaccine (Vero cell) in Argentine healthy population aged between 18 and 85 years old.
Description: All confirmed COVID -19 cases 14 days after the full course of vaccination among healthy population aged between 18 and 85 years old.Measure: Incidence of COVID-19 cases after two-doses of vaccination Time: 14 days after the full course of vaccination
Description: The protective level of Anti-SARS-CoV-2 NtAbsMeasure: Anti-SARS-CoV-2 neutralizing antobody (NtAb) (immunological surrogate endpoint) Time: 14 days after 2-dose of immunization.
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports